Update shared on 23 Nov 2025
Fair value Decreased 0.27%Analysts have slightly reduced their price target for InnoCare Pharma from ¥18.38 to ¥18.33. This change reflects updated assumptions about growth, profitability, and market trends.
What's in the News
- First patient dosed in clinical trial of ICP-B794, a novel B7-H3 targeted antibody-drug conjugate, for solid tumors including lung, esophageal, and prostate cancers (Key Developments).
- New data presented for zurletrectinib (ICP-723), showing a 90% objective response rate in pediatric and adolescent patients with NTRK fusion-positive solid tumors and overcoming resistance to first-generation TRK inhibitors (Key Developments).
- HIBRUKA (orelabrutinib) approved by Singapore's Health Sciences Authority for treatment of relapsed or refractory marginal zone lymphoma in adults, expanding regional access (Key Developments).
- Upcoming board meeting is scheduled for November 13, 2025, to review and approve unaudited third quarterly results (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has decreased marginally from ¥18.38 to ¥18.33.
- Discount Rate has risen slightly, moving from 7.03% to 7.19%.
- Revenue Growth expectation has declined modestly, from 31.23% to 30.46%.
- Net Profit Margin is projected to increase, rising from 3.45% to 3.95%.
- Future P/E ratio has increased significantly, from 195.47x to 367.22x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.